Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · RxSight, Inc. (RXST)

RxSight withdraws 2026 guidance as Q2 product sales fall 19% to $27.2 million

Negative Impact 4 of 5 guidance Written later

RxSight reported second-quarter 2026 total revenue of $33.7 million, roughly flat with the prior year, but product sales fell 19% to $27.2 million, and the net loss was $12.1 million, or $0.29 per share. The company withdrew its 2026 guidance in connection with the appointment of new President and CEO Aziz Mottiwala, and said it will resume formal guidance in early 2027.

Key points

  • Total revenue was $33.7 million, including $6.5 million from the Alcon collaboration; product sales were $27.2 million versus $33.6 million in the prior-year quarter.
  • Gross margin excluding the Alcon collaboration was 71.2%, down from 74.9%, which the company attributed to inventory-related costs.
  • Net loss was $12.1 million ($0.29 per share), compared with $11.8 million ($0.29 per share) a year earlier; adjusted net loss was $4.6 million ($0.11 per share) versus $3.3 million ($0.08).
  • 2026 guidance was withdrawn; cash, cash equivalents and short-term investments totaled $208.8 million as of June 30, 2026.

The filing

CompanyRxSight, Inc. (RXST)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:15 PM ET
Accession number0001193125-26-335150

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.